Metoclopramide vs Cerenia Dogs Anti-Nausea

Of course. This is a common and important clinical decision. Let's break down the pharmacology and practical application of metoclopramide versus maropitant.

Mechanism of Action & Efficacy

* Maropitant (Cerenia®): This is a neurokinin-1 (NK1) receptor antagonist. It works by blocking the action of Substance P in the nucleus tractus solitarius (the emetic center). Think of Substance P as the final common pathway for virtually all emetic stimuli, both central (CRTZ) and peripheral (visceral). By blocking it, maropitant provides very broad-spectrum and potent anti-emetic coverage. It's generally considered our most effective single-agent anti-emetic.
* Metoclopramide: This is primarily a D2-dopamine receptor antagonist that acts on the chemoreceptor trigger zone (CRTZ). It's effective against centrally-acting emetogens (e.g., uremic toxins, certain drugs). At higher doses, it also has weak 5-HT3 antagonist effects, which can help with visceral nausea. Its mechanism is narrower than maropitant's, making it less effective for severe visceral disease or motion sickness.

Clinical Decision-Making: When to Choose One Over the Other

Choose Maropitant as your first-line agent for:
* Undifferentiated vomiting: When the cause is unknown, its broad-spectrum activity is superior.
* Chemotherapy-induced vomiting: It is the standard of care due to its high efficacy.
* Motion sickness: It is labeled and highly effective for this indication.
* Severe vomiting (e.g., pancreatitis, parvovirus): Its potency is needed to break the emetic cycle.

Choose Metoclopramide when:
* A prokinetic effect is desired: This is metoclopramide's key advantage. It is excellent for functional ileus, delayed gastric emptying, or post-operative GI stasis. Maropitant has no prokinetic properties.
* Cost is a significant factor: Generic metoclopramide is substantially cheaper, especially for a continuous rate infusion (CRI) in a hospitalized patient.
* As an adjunct: In severe cases, I sometimes use a metoclopramide CRI for its prokinetic and mild anti-emetic effects alongside maropitant for potent emesis control.

Dosing & Administration

Metoclopramide's very short half-life (~90 minutes) is its biggest limitation for intermittent dosing. A dog receiving a dose every 8 hours is likely experiencing breakthrough nausea for much of that interval. For any hospitalized patient requiring sustained anti-emetic and prokinetic support, a CRI at 1-2 mg/kg/day IV is the standard of care. This provides steady-state plasma concentrations, maximizing efficacy while minimizing the risk of extrapyramidal side effects associated with high peak levels from bolus dosing.

Adverse Effects & Interactions

* Metoclopramide: The primary concern is extrapyramidal signs (agitation, tremors, frantic behavior) from central dopamine antagonism. This risk is low at CRI doses but increases with high boluses. Crucially, do not co-administer with phenothiazines like acepromazine, as they are also dopamine antagonists and their effects will be additive, significantly increasing the risk of adverse neurologic signs. It is also contraindicated in cases of GI obstruction.
* Maropitant: It has a very wide safety margin. The most common side effect is pain on subcutaneous injection due to the citrate buffer; keeping the vial refrigerated can mitigate this. While it is a moderate inhibitor of the CYP2D15 enzyme, clinically significant drug interactions are not commonly reported.

The Bottom Line

For pure anti-emetic efficacy, maropitant is the superior choice due to its broad, potent mechanism. However, metoclopramide remains an indispensable tool, primarily for its prokinetic effects in managing GI stasis, best administered as a CRI. The choice often comes down to whether you are treating vomiting alone (maropitant) or vomiting with concurrent ileus (metoclopramide, or both).